Orchid Pharma antibiotic API plant passes US FDA inspection

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Pharmaceutical drug

Orchid Pharma antibiotic API plant passes US FDA inspection
API firm Orchid Pharma has passed a US Food and Drug Administration (FDA) inspection at its facility in Tamil Nadu, India.

The facility in Alathur was visited by the US regulator last August according to Orchid, which announced it received an FDA Establishment Inspection Report (EIR) in a filing​ on the Bombay Stock Exchange (BSE) today. 

Orchid makes antibiotic active pharmaceutical ingredients (APIs) – primarily cephalosporin - at the site.

Operations at the facility were suspending in December​ as a result of flooding, which had a negative impact on the firm according to managing director K Raghavendra Rao.

Despite the business interruption sustained on account of unprecedented torrential rains in December 2015, the company is confident of regaining the traction on account of growth measures being initiated including launch of new products and long term financial arrangements​.”

Related news

Show more

Related products

show more

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars